Who makes Haemoblock?

Haemoblock is developed by Center for Vascular Pathology, Moscow.

What development phase is Haemoblock in?

Haemoblock is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Haemoblock

Center for Vascular Pathology, Moscow · FDA-approved active Small molecule Quality 0/100

Haemoblock, marketed by the Center for Vascular Pathology in Moscow, is a drug currently available in the market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and protected intellectual property. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Haemoblock
Sponsor	Center for Vascular Pathology, Moscow
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Application of the "Haemoblock" in Pacemaker Patients
A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results